Ceska a Slovenska Farmacie最新文献_第5页

Therapeutic monitoring of antipsychotics with a focus on lurasidone and its dosing. 抗精神病药物的治疗监控，重点是鲁拉西酮及其剂量。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Z Strašilová, M Turjap, J Juřica

引用次数: 0

High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. 高剂量与低剂量亚叶酸蛋白联合氟尿嘧啶治疗结直肠癌。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Jan Juřica, Pavlína Šuverová, Roman Goněc, Stanislav Synek, Miroslav Turjap

{"title":"High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy.","authors":"Jan Juřica, Pavlína Šuverová, Roman Goněc, Stanislav Synek, Miroslav Turjap","doi":"","DOIUrl":"","url":null,"abstract":"The problem of unavailability of drugs and shortages have been a common problem in recent years. Shortages may threaten some treatment regimens for oncological patients. This article presents a systematic review of studies evaluating the efficacy and safety of chemotherapy regimens combining fluorouracil and standard or low-dose leucovorin in treating colorectal cancer. A total of 13 prospective and retrospective studies were included in the review. Meta-analyses and review papers were excluded. It is apparent from the systematic review that a lower dose of leucovorin does not fundamentally affect the efficacy of regimens combining 5-fluorouracil with leucovorin in treating patients with colorectal cancer. Similarly, even in the case of safety, reducing the dose of leucovorin did not influence the frequency and severity of observed adverse effects. Surprisingly, in three studies, some of the adverse effects occurred more often with the higher dose of leucovorin. Furthermore, the article presents the results of a questionnaire survey of the management of leucovorin shortages at the departments of preparation of cytostatics (N = 46) within the Czech Republic. In total, 35 workplaces provided feedback. In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 3","pages":"107-112"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10125012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimicrobial properties of the new combined dental gel. 新型复合牙胶的抗菌性能。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Nataliia Dev Atkina

引用次数: 0

General intravenous anesthetics - pharmacodynamics, pharmacokinetics and chiral properties. 全身静脉麻醉药——药效学、药代动力学和手性特性。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Ružena Čižmáriková, Ladislav Habala, Mário Markulia

引用次数: 0

Hyperferritinemia as a factor associated with poor prognosis in COVID-19 patients. 高铁蛋白血症是 COVID-19 患者预后不良的一个相关因素。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Nuhad Mohammed Al-Dulaimi, Mahmood Jassim Mohammed, Saad T Mutlk, Khalid F Al-Rawi, Hameed Hussein Ali, Bilal J M Aldahham, Faisal Al-Ani, Osamah Al-Ani, Yaqout A Hamed, Aus T Ali

{"title":"Hyperferritinemia as a factor associated with poor prognosis in COVID-19 patients.","authors":"Nuhad Mohammed Al-Dulaimi, Mahmood Jassim Mohammed, Saad T Mutlk, Khalid F Al-Rawi, Hameed Hussein Ali, Bilal J M Aldahham, Faisal Al-Ani, Osamah Al-Ani, Yaqout A Hamed, Aus T Ali","doi":"","DOIUrl":"","url":null,"abstract":"Worldwide, hundreds of millions of people have been infected with COVID-19 since December 2019; however, about 20% or less developed severe symptoms. The main aim of the current study was to assess the relationship between the severity of Covid-19 and different clinical and laboratory parameters. A total number of 466 Arabs have willingly joined this prospective cohort. Out of the total number, 297 subjects (63.7%) had negative COVID-19 tests, and thus, they were recruited as controls, while 169 subjects (36.3%) who tested positive for COVID-19 were enrolled as cases. Out of the total number of COVID-19 patients, 127 (75.15%) presented with mild symptoms, and 42 (24.85%) had severe symptoms. The age range for the participants was 20 to 82 years. Compared with controls, the severity of the disease was associated with significantly high ferritin levels (P < 0.001). The severity of the disease was also associated with a significant increase in C-reactive protein (P < 0.001), D-dimer (P < 0.001), white blood cell count (WBC) (P < 0.01), IgM (P < 0.001), and Granulocytes (P < 0.01). In addition, severe COVID-19 symptoms in the current study were associated with a significant decrease in lymphocytes (P < 0.01). There was a four-fold increase in serum ferritin levels in COVID-19 patients presented with severe symptoms upon admission. The former was associated with significantly high levels of CRP and D-dimer. Thus, hyperferritinemia, together with high CRP and D-dimer concentrations, may serve as reliable predictors for disease severity and poor prognosis in Arabs with COVID-19.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 5","pages":"223-232"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation and evaluation of spray-dried inhalable microparticles from carrier mixtures. 利用载体混合物制备喷雾干燥可吸入微颗粒并对其进行评估。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Andrea Peštálová, Karolína Molatová, Jan Gajdziok

{"title":"Preparation and evaluation of spray-dried inhalable microparticles from carrier mixtures.","authors":"Andrea Peštálová, Karolína Molatová, Jan Gajdziok","doi":"","DOIUrl":"","url":null,"abstract":"The formulation of microparticles composed of a mixture of carriers represents an innovative approach for lung drug delivery of dry powder. The carriers used can significantly influence the properties of the microparticles, such as size, shape, surface area, hygroscopicity, or aggregation, thus improving the aerosolization of the drugs after inhalation. The properties mentioned above are crucial for effective pulmonary therapy. The combination of carriers of a carbohydrate nature and gelling agents is advantageous for controlled drug release. The experimental work aimed to prepare by spray drying and subsequently evaluate ten batches of microparticles composed of sugar-based carriers (mannitol, maltodextrin, dextran) and gelling polymers (chitosan, chondroitin sulfate) and to select a suitable combination for follow-up experimental work aimed at drug incorporation into the microparticle matrix. The most suitable parameters were exhibited by batches whose aerodynamic diameter was close to 5 µm, particles prepared from a combination of mannitol and dextran, chitosan and chondroitin, or maltodextrin and chondroitin. These batches also showed the highest fine particle fraction value (> 43%). From a processability point of view, the batch with maltodextrin and chondroitin is preferable due to the lower viscosity of the dispersion and the more regular shape of the final microparticles.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 5","pages":"214-222"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome. 提高代谢综合征背景下非酒精性脂肪肝患者联合使用槲皮素进行降脂治疗的效率。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Lyudmila Kravchenko, Liana Unhurian, Svetlana K Tiuzhinska, Yana Ivanova, Maya Obrazenko, Liudmyla Zahorodnya, Tetiana Yamilova

{"title":"Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome.","authors":"Lyudmila Kravchenko, Liana Unhurian, Svetlana K Tiuzhinska, Yana Ivanova, Maya Obrazenko, Liudmyla Zahorodnya, Tetiana Yamilova","doi":"","DOIUrl":"","url":null,"abstract":"The article analyzes the results of a set of biochemical indicators in the course of treatment with the combined use of rosuvastatin with quercetin in patients with metabolic syndrome (MS) combined with non-alcoholic fatty liver disease. Changes in blood biochemical parameters have been identified and presented with MS, essential for revealing generalbiological mechanisms development and interrelationship between the components of MS and non-alcoholic fatty liver. The effect of an increase in free cholesterol and triglycerides and activation of freeradical oxidation of lipids followed by theaccumulation of oxidative stress products was noted. In the course of long-term hypolipidemic therapy (90 days), 86 patients with non-alcoholic fatty liver disease on the background of metabolic syndrome were previously divided into 2 groups: a comparison group (45 patients), who weretreated with basic therapy - only rosuvastatin, the main group (41 patients) received quercetin together with rosuvastatin -40 mg 3 times a day, clinical and laboratory-instrumental examinations were carried out. On the 90th day of treatment, positive results in the functional state of the liver and lipid spectrum of the blood wereregistered in all patients. A more significant advantage of the therapeutic combination of rosuvastatin with quercetin was proved. The inclusion of quercetin contributed to reducing the intensity of oxidative stress and enhancing antioxidant protection activity, resultingin a decrease in apoptosis of hepatocytes (cytokeratin-18 level was 1.27 times decreased). The studies have shown the feasibility of combined use of quercetin with rosuvastatin for the prevention of the development and progression of metabolic disorders associated with non-alcoholic fatty liver disease.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 6","pages":"296-302"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colour and content of some metals in honey. 蜂蜜中某些金属的颜色和含量。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Jan Šubert, Jozef Kolář, Jozef Čižmárik

引用次数: 0

Friedrich Jakub Fuker and his universal preventive tincture. 弗里德里希·雅克布·福克和他的通用预防药剂。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

František Šimon

引用次数: 0

New trends in advanced parkinson disease stage therapy. 晚期帕金森病分期治疗的新趋势。

Ceska a Slovenska Farmacie Pub Date : 2023-01-01

Mária Kolesárová, Ondrej Franko, Dalibor Kolesár, Andrea Gažová, Ján Kyselovič

{"title":"New trends in advanced parkinson disease stage therapy.","authors":"Mária Kolesárová, Ondrej Franko, Dalibor Kolesár, Andrea Gažová, Ján Kyselovič","doi":"","DOIUrl":"","url":null,"abstract":"The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing \"off\" periods in patients has also been noted. In the case of Duodopa and DBS, the \"off\" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10823792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0